Cristina Borin

Cristina Borin

Auto-generated profile, based on publicly available information

Cristina Borin

Ghent University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Blood
Verified
Journal Article
Closed access
JKJonas De Kesel
Jonas De Kesel
IFIgor Fijalkowski
Igor Fijalkowski
TPTim Pieters
Tim Pieters
CBCristina Borin
Cristina Borin
KCKasper Thorhauge Christensen
Kasper Thorhauge Christensen
PNPanagiotis Ntziachristos
Panagiotis Ntziachristos
RNA homeostasis is dysregulated in cancer and impacts disease progression and therapy resistance. N6-methyladenosine (m6A), the most abundant epitranscriptomic modification in eukaryotic mRNA, plays a pivotal role in RNA biology, affecting transcript stability, translation, and splicing. Our study uncovers the extensive m6A changes in T-cell acute lymphoblastic leukemia (T-ALL) patient samples for the first time. It reveals m6A's regulatory role in the oncogenic MYC and cholesterol biosynthesis pathways. In addition, we discovered that T-ALL is highly dependent on the m6A reader heterogeneous nuclear ribonucleoprotein C (HNRNPC). HNRNPC is transcriptionally controlled by MYC and is an essential regulator of m6A-modified transcripts. Consequently, transcriptional silencing of HNRNPC profoundly impairs oncogenic pathways and critically diminishes leukemia cell growth. Additionally, the levels of the m6A demethylase fat mass and obesity-associated (FTO) are significantly elevated in T-ALL cells compared to normal cells, and to other types of leukemia. Targeting FTO shows therapeutic potential in preclinical disease models and synergizes with clinically relevant therapeutics. Our findings underscore the integral role of RNA methylation in orchestrating cancer cell oncogene expression and metabolism and highlight promising novel therapeutic avenues for the treatment of T-cell leukemia.

9 December 2022 in Science Advances
Verified
Journal Article
Open access
QJQi Jin
Qi Jin
BDBlanca Gutierrez Diaz
Blanca Gutierrez Diaz
TPTim Pieters
Tim Pieters
YZYalu Zhou
Yalu Zhou
SNSonali Narang
Sonali Narang
PNPanagiotis Ntziachristos
Panagiotis Ntziachristos
Dysregulation of kinase signaling pathways favors tumor cell survival and therapy resistance in cancer. Here, we reveal a posttranslational regulation of kinase signaling and nuclear receptor activity via deubiquitination in T cell acute lymphoblastic leukemia (T-ALL). We observed that the ubiquitin-specific protease 11 (USP11) is highly expressed and associates with poor prognosis in T-ALL. USP11 ablation inhibits leukemia progression in vivo, sparing normal hematopoiesis. USP11 forms a complex with USP7 to deubiquitinate the oncogenic lymphocyte cell–specific protein-tyrosine kinase (LCK) and enhance its activity. Impairment of LCK activity leads to increased glucocorticoid receptor (GR) expression and glucocorticoids sensitivity. Genetic knockout of USP7 improved the antileukemic efficacy of glucocorticoids in vivo. The transcriptional activation of GR target genes is orchestrated by the deubiquitinase activity and mediated via an increase in enhancer-promoter interaction intensity. Our data unveil how dysregulated deubiquitination controls leukemia survival and drug resistance, suggesting previously unidentified therapeutic combinations toward targeting leukemia.

10 September 2026 in Blood
Verified
Journal Article
Closed access
CBCristina Borin
Cristina Borin
PNPanagiotis Ntziachristos
Panagiotis Ntziachristos

6 October 2026 in Blood Neoplasia
Verified
Journal Article
Open access
IFIgor Fijalkowski
Igor Fijalkowski
CBCristina Borin
Cristina Borin
TCTibo Coulier
Tibo Coulier
CMChristian Marinaccio
Christian Marinaccio
CHCuijuan Han
Cuijuan Han
PNPanagiotis Ntziachristos
Panagiotis Ntziachristos